Recommended Topic Related To:

Valtrex

"Jan. 5, 2012 -- People with genital herpes can still infect their sex partners -- even if they are taking anti-herpes drugs that prevent herpes outbreaks.

Even when they don't have an active herpes outbreak, people who carry genital h"...

Valtrex

Indications
Dosage
How Supplied

INDICATIONS

Adult Patients

Cold Sores (Herpes Labialis)

VALTREX® (valacyclovir hydrochloride) Caplets are indicated for treatment of cold sores (herpes labialis). The efficacy of VALTREX (valacyclovir hydrochloride) initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.

Genital Herpes

Initial Episode: VALTREX (valacyclovir hydrochloride) is indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX (valacyclovir hydrochloride) when initiated more than 72 hours after the onset of signs and symptoms has not been established.

Recurrent Episodes: VALTREX (valacyclovir hydrochloride) is indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX (valacyclovir hydrochloride) when initiated more than 24 hours after the onset of signs and symptoms has not been established.

Suppressive Therapy: VALTREX (valacyclovir hydrochloride) is indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults. The efficacy and safety of VALTREX (valacyclovir hydrochloride) for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-infected patients have not been established.

Reduction of Transmission: VALTREX (valacyclovir hydrochloride) is indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of VALTREX (valacyclovir hydrochloride) for the reduction of transmission of genital herpes beyond 8 months in discordant couples has not been established. The efficacy of VALTREX (valacyclovir hydrochloride) for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines).

Herpes Zoster

VALTREX (valacyclovir hydrochloride) is indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of VALTREX (valacyclovir hydrochloride) when initiated more than 72 hours after the onset of rash and the efficacy and safety of VALTREX (valacyclovir hydrochloride) for treatment of disseminated herpes zoster have not been established.

Pediatric Patients

Cold Sores (Herpes Labialis)

VALTREX (valacyclovir hydrochloride) is indicated for the treatment of cold sores (herpes labialis) in pediatric patients ≥ 12 years of age. The efficacy of VALTREX (valacyclovir hydrochloride) initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.

Chickenpox

VALTREX (valacyclovir hydrochloride) is indicated for the treatment of chickenpox in immunocompetent pediatric patients 2 to < 18 years of age. Based on efficacy data from clinical studies with oral acyclovir, treatment with VALTREX (valacyclovir hydrochloride) should be initiated within 24 hours after the onset of rash [see Clinical Studies].

Limitations of Use

The efficacy and safety of VALTREX (valacyclovir hydrochloride) have not been established in:

  • Immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients with a CD4+ cell count ≥ 100 cells/mm³.
  • Patients < 12 years of age with cold sores (herpes labialis).
  • Patients < 2 years of age or ≥ 18 years of age with chickenpox.
  • Patients < 18 years of age with genital herpes.
  • Patients < 18 years of age with herpes zoster.
  • Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection.

DOSAGE AND ADMINISTRATION

  • VALTREX (valacyclovir hydrochloride) may be given without regard to meals.
  • Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg VALTREX (valacyclovir hydrochloride) Caplets for use in pediatric patients for whom a solid dosage form is not appropriate.

Adult Dosing Recommendations

Cold Sores (Herpes Labialis)

The recommended dosage of VALTREX (valacyclovir hydrochloride) for treatment of cold sores is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning).

Genital Herpes

Initial Episode: The recommended dosage of VALTREX (valacyclovir hydrochloride) for treatment of initial genital herpes is 1 gram twice daily for 10 days. Therapy was most effective when administered within 48 hours of the onset of signs and symptoms.

Recurrent Episodes: The recommended dosage of VALTREX (valacyclovir hydrochloride) for treatment of recurrent genital herpes is 500 mg twice daily for 3 days. Initiate treatment at the first sign or symptom of an episode.

Suppressive Therapy: The recommended dosage of VALTREX (valacyclovir hydrochloride) for chronic suppressive therapy of recurrent genital herpes is 1 gram once daily in patients with normal immune function. In patients with a history of 9 or fewer recurrences per year, an alternative dose is 500 mg once daily.

In HIV-infected patients with a CD4+ cell count ≥ 100 cells/mm³, the recommended dosage of VALTREX (valacyclovir hydrochloride) for chronic suppressive therapy of recurrent genital herpes is 500 mg twice daily.

Reduction of Transmission: The recommended dosage of VALTREX (valacyclovir hydrochloride) for reduction of transmission of genital herpes in patients with a history of 9 or fewer recurrences per year is 500 mg once daily for the source partner.

Herpes Zoster

The recommended dosage of VALTREX (valacyclovir hydrochloride) for treatment of herpes zoster is 1 gram 3 times daily for 7 days. Therapy should be initiated at the earliest sign or symptom of herpes zoster and is most effective when started within 48 hours of the onset of rash.

Pediatric Dosing Recommendations

Cold Sores (Herpes Labialis)

The recommended dosage of VALTREX (valacyclovir hydrochloride) for the treatment of cold sores in pediatric patients ≥ 12 years of age is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning).

Chickenpox

The recommended dosage of VALTREX (valacyclovir hydrochloride) for treatment of chickenpox in immunocompetent pediatric patients 2 to < 18 years of age is 20 mg/kg administered 3 times daily for 5 days. The total dose should not exceed 1 gram 3 times daily. Therapy should be initiated at the earliest sign or symptom [see Use in Specific Populations, CLINICAL PHARMACOLOGY, Clinical Studies].

Extemporaneous Preparation of Oral Suspension

Ingredients and Preparation per USP-NF

VALTREX (valacyclovir hydrochloride) Caplets 500 mg, cherry flavor, and Suspension Structured Vehicle USP-NF (SSV). Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) should be prepared in lots of 100 mL.

Prepare Suspension at Time of Dispensing as Follows
  • Prepare SSV according to the USP-NF.
  • Using a pestle and mortar, grind the required number of VALTREX (valacyclovir hydrochloride) 500 mg Caplets until a fine powder is produced (5 VALTREX (valacyclovir hydrochloride) Caplets for 25 mg/mL suspension; 10 VALTREX (valacyclovir hydrochloride) Caplets for 50 mg/mL suspension).
  • Gradually add approximately 5 mL aliquots of SSV to the mortar and triturate the powder until a paste has been produced. Ensure that the powder has been adequately wetted.
  • Continue to add approximately 5 mL aliquots of SSV to the mortar, mixing thoroughly between additions, until a concentrated suspension is produced, to a minimum total quantity of 20 mL SSV and a maximum total quantity of 40 mL SSV for both the 25 mg/mL and 50 mg/mL suspensions.
  • Transfer the mixture to a suitable 100 mL measuring flask.
  • Transfer the cherry flavor* to the mortar and dissolve in approximately 5 mL of SSV. Once dissolved, add to the measuring flask.
  • Rinse the mortar at least 3 times with approximately 5 mL aliquots of SSV, transferring the rinsing to the measuring flask between additions.
  • Make the suspension to volume (100 mL) with SSV and shake thoroughly to mix.
  • Transfer the suspension to an amber glass medicine bottle with a child-resistant closure.
  • The prepared suspension should be labeled with the following information “Shake well before using. Store suspension between 2° to 8°C (36° to 46°F) in a refrigerator. Discard after 28 days.”

*The amount of cherry flavor added is as instructed by the suppliers of the cherry flavor.

Patients With Renal Impairment

Dosage recommendations for adult patients with reduced renal function are provided in Table 1 [see Use in Specific Populations, CLINICAL PHARMACOLOGY]. Data are not available for the use of VALTREX (valacyclovir hydrochloride) in pediatric patients with a creatinine clearance < 50 mL/min/1.73 m².

Table 1: VALTREX (valacyclovir hydrochloride) Dosage Recommendations for Adults With Renal Impairment

Indications Normal Dosage Regimen (Creatinine Clearance ≥ 50 mL/min) Creatinine Clearance (mL/min)
30-49 10-29 < 10
Cold sores (Herpes labialis) Two 2 gram doses taken Two 1 gram doses taken Two 500 mg doses taken 500 mg single dose
Do not exceed 1 day of treatment 12 hours apart 12 hours apart 12 hours apart  
Genital herpes: Initial episode 1 gram every 12 hours no reduction 1 gram every 24 hours 500 mg every 24 hours
Genital herpes: Recurrent episode 500 mg every 12 hours no reduction 500 mg every 24 hours 500 mg every 24 hours
Genital herpes: Suppressive therapy
  Immunocompetent patients 1 gram every 24 hours no reduction 500 mg every 24 hours 500 mg every 24 hours
  Alternate dose for immunocompetent patients with ≤ 9 recurrences/year 500 mg every 24 hours no reduction 500 mg every 48 hours 500 mg every 48 hours
  HIV-infected patients 500 mg every 12 hours no reduction 500 mg every 24 hours 500 mg every 24 hours
  Herpes zoster 1 gram every 8 hours 1 gram every 12 hours 1 gram every 24 hours 500 mg every 24 hours

Hemodialysis

Patients requiring hemodialysis should receive the recommended dose of VALTREX (valacyclovir hydrochloride) after hemodialysis. During hemodialysis, the half-life of acyclovir after administration of VALTREX (valacyclovir hydrochloride) is approximately 4 hours. About one third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session.

Peritoneal Dialysis

There is no information specific to administration of VALTREX (valacyclovir hydrochloride) in patients receiving peritoneal dialysis. The effect of chronic ambulatory peritoneal dialysis (CAPD) and continuous arteriovenous hemofiltration/dialysis (CAVHD) on acyclovir pharmacokinetics has been studied. The removal of acyclovir after CAPD and CAVHD is less pronounced than with hemodialysis, and the pharmacokinetic parameters closely resemble those observed in patients with end-stage renal disease (ESRD) not receiving hemodialysis. Therefore, supplemental doses of VALTREX (valacyclovir hydrochloride) should not be required following CAPD or CAVHD.

HOW SUPPLIED

Dosage Forms And Strengths

Caplets
  • 500 mg: blue, film-coated, capsule-shaped tablets printed with “VALTREX (valacyclovir hydrochloride) 500 mg.”
  • 1 gram: blue, film-coated, capsule-shaped tablets, with a partial scorebar on both sides, printed with “VALTREX (valacyclovir hydrochloride) 1 gram.”

Storage And Handling

VALTREX (valacyclovir hydrochloride) Caplets (blue, film-coated, capsule-shaped tablets) containing valacyclovir hydrochloride equivalent to 500 mg valacyclovir and printed with “VALTREX (valacyclovir hydrochloride) 500 mg.”

Bottle of 30 (NDC 0173-0933-08).
Bottle of 90 (NDC 0173-0933-10).
Unit dose pack of 100 (NDC 0173-0933-56).

VALTREX (valacyclovir hydrochloride) Caplets (blue, film-coated, capsule-shaped tablets, with a partial scorebar on both sides) containing valacyclovir hydrochloride equivalent to 1 gram valacyclovir and printed with “VALTREX (valacyclovir hydrochloride) 1 gram.”

Bottle of 30 (NDC 0173-0565-04).
Bottle of 90 (NDC 0173-0565-10).

Storage

Store at 15° to 25°C (59° to 77°F). Dispense in a well-closed container as defined in the USP.

Distributed by: GlaxoSmithKline Research Triangle Park, NC 27709. Manufactured by: GlaxoSmithKline Research Triangle Park, NC 27709 or DSM Pharmaceuticals, Inc. Greenville, NC 27834. March 2010

Last reviewed on RxList: 1/24/2011
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Valtrex - User Reviews

Valtrex User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Valtrex sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Sex & Relationships

Get tips to boost your love life.


NIH talks about Ebola on WebMD